CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report)’s share price gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $78.73, but opened at $82.49. CRISPR Therapeutics shares last traded at $78.25, with a volume of 725,141 shares changing hands. The company reported $1.10 earnings […]
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target increased by stock analysts at Wells Fargo & Company from $55.00 to $70.00 in a research note issued to investors on Thursday, Benzinga reports. The firm presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective suggests a potential […]
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its target price boosted by equities research analysts at Royal Bank of Canada from $57.00 to $66.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a “sector perform” rating on the stock. Royal Bank of Canada’s price objective would indicate […]
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) CEO Samarth Kulkarni sold 6,370 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total value of $507,497.90. Following the sale, the chief executive officer now owns 194,257 shares in […]
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price objective raised by analysts at Royal Bank of Canada from $57.00 to $66.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “sector perform” rating on the stock. Royal Bank of Canada’s target price indicates a potential downside […]